Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910784 | Lung Cancer | 2015 | 4 Pages |
Abstract
This is the first report on outcomes for stage II NSCLC patients receiving CRT as definitive therapy. Survival approximates stage III CRT patients from historical phase III trials. As an increasing aging population may parallel a rise in medically inoperable stage II patients, this study can provide useful information when reviewing treatment options.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sagus Sampath, Matthew Hall, Timothy E. Schultheiss,